Jul 19, 2018 waldenstrom macroglobulinemia wm is a type of nonhodgkin lymphoma nhl. Primary therapy of waldenstrom macroglobulinemia wm with weekly bortezomib, lowdose dexamethasone, and rituximab bdr. Her evaluation revealed a hypochromic anemia and sedimentation rate of 122 mmh. Waldenstrom macroglobulinemia wm is a rare type of nonhodgkin lymphoma. This condition used to be called waldenstroms macroglobulinemia, so some people refer to it as waldenstroms. Waldenstrom macroglobulinemia mimicking temporal arteritis. Treatment and prognosis of waldenstrom macroglobulinemia. International waldenstroms macroglobulinemia foundation. Waldenstrom macroglobulinemia wm is a cancer of the b lymphocytes a type of white blood cell. Cyclophosphamide, bortezomib and dexamethasone cybord. Signs and symptoms of waldenstrom macroglobulinemia what cancer patients, their families, and caregivers need to know about the coronavirus. Our multidisciplinary team appraised studies published or presented up to december 2015 to provide. Remstein ed, hanson ca, kyle ra, hodnefield jm, kurtin pj. Waldenstrom macroglobulinemia wm, is a type of cancer affecting two types of b cells.
Genomic landscape of cxcr4 mutations in waldenstrom. The ocular manifestations of waldenstroms macroglobulinemia. In fact, we found a study which did not link wm to any specific occupational exposure and another study which looked at a number of possible environmental exposures including asbestos and reported a possible association with exposure to. This condition is also called waldenstrom macroglobulinemia after the professor who was the first to define individuals who were suffering with this condition. See more ideas about herbal treatment, polymyalgia rheumatica and polymyalgia rheumatica symptoms. Waldenstrom macroglobulinemia wm is a type of nonhodgkin lymphoma nhl. The 2018 esmo clinical practice guidelines on waldenstroms macroglobulinemia wm are based on results from recent studies and updated analyses. Waldenstrom macroglobulinemia wm is a rare lymphoplasmacytic lymphoma with many patients showing progressive disease despite the recent advances of novel therapeutic agents. Singleagent ibrutinib is highly active in refractory waldenstrom s macroglobulinemia, with results that eclipse other treatment options, says an editorialist. It is characterized by the presence of a high level of a macroglobulin immunoglobulin m igm, elevated serum viscosity, and the presence of a lymphoplasmacytic infiltrate in the bone marrow. Mar 23, 2015 the world health organization defines waldenstrom macroglobulinemia wm as a lymphoplasmacytic lymphoma associated with a monoclonal immunoglobulin m igm protein 1. People over age 50 get waldenstroms macroglobulinemia more often.
Waldenstrom macroglobulinemia makroeglobulihneemeuh is a rare type of cancer that begins in the white blood cells. Signs and symptoms of waldenstrom macroglobulinemia. Nccn clinical practice guidelines in oncology nccn. About 1,000 to 1,500 people are diagnosed with wm each year in the united states. Waldenstrom macroglobulinemia is thought to result from a combination of genetic changes. Introduction wholegenome sequencing has revealed cxcr4 as the second most frequent somatic mutation, identi.
Mixed lytic and blastic bone lesions as a presenting. How i treat waldenstrom macroglobulinemia american society of. Although waldenstroms has no proven risk factors, certain things seem to make you more likely to develop it. The most common known genetic change associated with this condition is a mutation in the myd88 gene, which is found in more than 90 percent of affected individuals. How i treat waldenstrom macroglobulinemia blood american. Wm remains an incurable disease, with a median overall survival os of 8 years from diagnosis. Waldenstrom macroglobulinemia current management youtube. Full text new developments in the management of waldenstrom. Waldenstrom macroglobulinemia wm is a lowgrade bcell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin m. Waldenstrom in 1944, waldenstrom macroglobulinemia wm is an indolent lymphoma characterized by bone marrow infiltration with lymphoplasmacytic cells associated with a monoclonal immunoglobulin m igm protein figure 1. Pdf waldenstrom macroglobulinemia is a rare lymphoproliferative disorder with distinctive clinical features. Here you can find out all about waldenstrom macroglobulinemia, including risk factors, symptoms, how it is found, and how it is treated. Neuropathy is a process in which multiple nerves become diseased or damaged there are many causes for neuropathy the immune system plays a role, specifically in producing too much of a certain type of protein monoclonal gammopathy 3050% of individuals with waldenstroms macroglobulinemia develop neuropathy most of these individuals have a demyelinating neuropathy which is mild.
A rare complication of anticoagulant therapy in a patient with waldenstrom macroglobulinemia clin case rep rev, 2015 doi. Zeldenrust, yanhong wu, angela dispenzieri, peter j. Treatment and outcome patterns in european patients with. Blood first edition paper, prepublished online may 22, 2015. Waldenstroms macroglobulinemia md anderson cancer center. The cases presented in table 1 revealed waldenstrom macroglobulinemia wm, a bcell neoplasm resulting from the accumulation of clonal lymphoplasmacytic cells secreting a monoclonal immunoglobulin igm protein. Mar 27, 2015 waldenstrom macroglobulinemia wm is a bcell lymphoplasmacytic lymphoma characterized by monoclonal immunoglobulin m protein in the serum and infiltration of bone marrow with lymphoplasmacytic.
Ibrutinib was approved by the food and drug administration for the treatment of wm in 2015. Waldenstroms macroglobulinemia wm is a bcell neoplasm manifested by the accumulation. Bolognesi m 2015 diffuse alveolar hemorrhage dah syndrome. Long term follow up of this study was published in 2015. Waldenstrom macroglobulinemia genetic and rare diseases. There is no threshold for bm clonal cell infiltration, but individuals with less than 10% clonal cells have an indolent course 7 compared with. Further studies are needed to establish its efficacy against current standard treatments and to investigate whether outcomes can be improved with combination therapies. Jan, 2016 adam olszewski, md, of the alpert medical school of brown university talks about waldenstrom macroglobulinemia and how it is currently treated. We performed a prospective study of ibrutinib in 63 symptomatic patients with waldenstroms macroglobulinemia who had received at least one previous treatment, and we investigated the effect of myd88 and cxcr4 mutations on outcomes. Emg typically shows demyelinating pattern with antimyelin. It usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved. Wm is associated with the overproduction of proteins called igm antibodies. Pdf waldenstrom macroglobulinemia is a rare lymphoproliferative disorder with distinctive clinical.
The incidence of wmg is estimated to be about 5 per 1,000,000 people over the age of 50. Presence of igm monoclonal protein associated with. Waldenstrom macroglobulinemia wm is a lymphoproliferative disorder. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity. The diagnosis of wm requires a bone marrow bm biopsy showing infiltration by clonal lymphoplasmacytic cellslymphoplasmacytic lymphoma lpl and the presence of any amount of monoclonal igm, 5,6 detected by immunofixation electrophoresis. Waldenstrom macroglobulinemia american cancer society. What is new in the treatment of waldenstrom macroglobulinemia. Waldenstrom macroglobulinemia wm is a bcell lymphoplasmacytic lymphoma characterized by monoclonal immunoglobulin m protein in the serum and infiltration of bone marrow with lymphoplasmacytic. Treon sp, tripsas ck, ioakimidis l, et bruton tyrosine kinase inhibitor ibrutinib ternational prognostic scoring system for al.
Despite apparent morphologic and immunophenotypic heterogeneity, waldenstroms macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. Cyclophosphamide, bortezomib, and dexamethasone combination. A remarkable improvement in outcome of nearly all age groups of wm patients may be primarily a consequence of successful integration of anti. Jul 19, 2018 waldenstrom macroglobulinemia wm is rare, with an incidence rate of about 3 cases per million people per year in the united states. Waldenstrom macroglobulinemia symptoms and causes mayo clinic. The combination of bortezomib, dexamethasone, and cyclophosphamide cybord has been studied in multiple myeloma showing overall response rate of 88%, and being used as one of the standard of. Presents with igm secretion, and, in less than 15% of cases, also features lymphadenopathy and s.
The ocular complications in this disease are being reported with increasing frequency with the spectrum of retinal changes ranging. Although wm remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the myd88 and cxcr4 genes further enhanced our. Dimopoulos ma, garciasanz r, gavriatopoulou m, et al. Waldenstrom macroglobulinemia wm is a bcell neoplasm. The cancer cells make large amounts of an abnormal protein called a macroglobulin. Acalabrutinib monotherapy in patients with waldenstrom. Oct 01, 20 waldenstrom macroglobulinemia is a chronic, slowgrowing lymphoproliferative disorder. With availability of a wider array of therapies, the management strategies have become increasingly complex. Waldenstrom macroglobulinemia wm is a bcell neoplasm manifested by the accumulation of clonal immunoglobulin igmsecreting lymphoplasmacytic cells. The initial findings showed that ibrutinib was highly active in. Longterm follow up of this study was published in 2015.
Macroglobulinemia is a disease of the reticuloendothelial system in which the signs and symptoms are associated with an abnormal protein having a high molecular weight. Pdf waldenstrom macroglobulinemia wm is an indolent. What is lymphoplasmacytic lymphoma lpl the worldwide coronavirus outbreak, declared a pandemic by the world health organization who on wednesday, march 11, continues to be of great concern to wm patients and caregivers around the world. Sometimes, waldenstrom macroglobulinemia wm isnt causing any symptoms when its first found. Dec 05, 2019 waldenstrom macroglobulinemia wm is an uncommon lymphoma. Ibrutinib remarkable in waldenstroms macroglobulinemia. If you have waldenstrom macroglobulinemia or are close to someone who does, knowing what to expect can help you cope. Prospective, multicenter study of the pci32765 has significant activity in pa waldenstrom macroglobulinemia. Dec 03, 2018 waldenstrom macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. The pathophysiologic hallmark is monoclonal igm production by a malignant lymphoplasmacytic clone that can cause damage to multiple organs. Anything that increases your chance of getting waldenstroms macroglobulinemia cancer is a risk factor. How i treat waldenstrom macroglobulinemia international. If you have waldenstrom macroglobulinemia, your bone marrow produces too many abnormal white blood cells that crowd out healthy blood cells.
The clinical and laboratory findings for a large series of newly diagnosed patients who presented to the wm clinic at the dana farber cancer institute a tertiary referral center are depicted in table 2. This study provides evidence that acalabrutinib is active as singleagent therapy with a manageable safety profile in patients with treatmentnaive, or relapse or refractory waldenstrom macroglobulinemia. Apr 09, 2015 cxcr4whim mutations confer in vitro resistance to ibrutinib. Jimenez c, sebastian e, del carmen chillon m, et al.
We present the case of a 64yearold man with bone pain caused by mixed lytic and blastic bone lesions. Waldenstroms macroglobulinemia nord national organization. Waldenstrom macroglobulinemia genetics home reference nih. World health organization classification of tumours of the haematopoietic and lymphoid tissues. Waldenstroms macroglobulinemia is a very rare disorder affecting about 1 in 3. The clinical manifestations of the disorder are hepatomegaly 20%, splenomegaly 15%, and lymphadenopathy 15% 2. Waldenstroms macroglobulinemia wm is lymphoplasmacytoid malignancy that affects b lymphocytes. Diagnosis and management of waldenstrom macroglobulinemia. Ibrutinib in previously treated waldenstroms macroglobulinemia. Waldenstrom macroglobulinemia to date, in nearly 90% of waldenstrom macroglobulinemia 4, 5. Wm is characterized by having high levels of a circulating antibody, immunoglobulin m igm, which is made and secreted by the cells involved in the disease. Herein, the mayo clinic cancer center myeloma, amyloidosis and dysproteinemia and lymphoma diseaseoriented groups, the multidisciplinary panels of experts with a collective experience of treating hundreds of waldenstrom macroglobulinemia wm cases, update their evidencebased recommendations for the management of wm.
Splenomegaly and lymphadenopathy as with case 2 are uncommon at initial presentation 1520%, although at later stages, extramedullary disease is more common up to 60% of patients. Although giant cell arteritis was believed to be a likely diagnosis, the findings of hepatomegaly, lymphadenopathy, a reversed albuminglobulin ratio, and an elevated serum concentration of immunoglobulin m led to a diagnosis of waldenstrom macroglobulinemia. Waldenstrom s macroglobulinemia wm is lymphoplasmacytoid malignancy that affects b lymphocytes. Neuropathy is a process in which multiple nerves become diseased or damaged there are many causes for neuropathy the immune system plays a role, specifically in producing too much of a certain type of. Cutaneous involvement of wm is rare, but various cutaneous manifestations have been reported.
Lymphoplasmacytic lymphoma with bone marrow involvement and igm monoclonal gammopathy of any concentration from swerdlow sh, campo e, harris nl, jaffe es, pileri sa, stein h, thiele j, vardiman jw eds. Of all bcell neoplasms, wm accounts for approximately 12% of diagnoses and is an indolent disease with a median survival quoted anywhere from 5. New recommendations are given regarding the role of myd88 l265p detection in the diagnosis of wm and the role of ibrutinib in the treatment of symptomatic wm. The diagnosis of wm is established by the presence of lymphoplasmacytic lymphoma in the bone marrow or other organs, a. The histopathologic observation of a blastic lesion obtained via biopsy confirmed the infiltration by lymphoplasmacytic lymphoma, with extensive plasmacytic differentiation.
21 587 1180 964 411 966 741 1593 145 699 1489 1352 1033 1049 203 311 801 796 1570 983 1268 306 757 1190 518 752 1364 846 752